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Summary
Estrogen plays an essential physiologic role in repro-
duction and a pathologic one in breast cancer. The
completion of the human genome has allowed the
identification of the expressed regions of protein-cod-
ing genes; however, little is known concerning the or-
ganization of their cis-regulatory elements. We have
mapped the association of the estrogen receptor (ER)
with the complete nonrepetitive sequence of human
chromosomes 21 and 22 by combining chromatin im-
munoprecipitation (ChIP) with tiled microarrays. ER
binds selectively to a limited number of sites, the ma-
jority of which are distant from the transcription start
sites of regulated genes. The unbiased sequence in-
terrogation of the genuine chromatin binding sites
suggests that direct ER binding requires the pres-
ence of Forkhead factor binding in close proximity.
Furthermore, knockdown of FoxA1 expression blocks
the association of ER with chromatin and estrogen-
induced gene expression demonstrating the neces-
sity of FoxA1 in mediating an estrogen response in
breast cancer cells.
Introduction
Estrogen is an essential regulator of female develop-
ment and reproductive function and has been impli-*Correspondence: myles_brown@dfci.harvard.educated as a causal factor in breast and endometrial can-
cers. Estrogen-regulated gene expression is mediated
by the action of two members of the nuclear receptor
family, ERα and ERβ, with ERα being dominant in both
breast epithelial cells and in breast cancer. Significant
progress has been made over the past decade in defin-
ing the complex interactions between chromatin and an
array of factors involved in ER-mediated gene expres-
sion (Halachmi et al., 1994; Metivier et al., 2003; Shang
and Brown, 2002; Shang et al., 2000), including the cy-
clic association of ER, p160 coactivators (such as AIB-1),
histone acetyl transferases (HAT), and chromatin modi-
fying molecules, such as p300/CBP and p/CAF, with
target promoters in an ordered temporal fashion (Meti-
vier et al., 2003; Shang et al., 2000).
In addition, a number of recent strategies including
gene expression profiling on microarrays have iden-
tified potential ER target genes in human breast cancer
cells and only a few cis-elements targeted directly by
ER have been identified to date. For example, estrogen
responsive elements (ERE) have been identified within
the 1 kb 5#-proximal region of the estrogen-regulated
genes TFF-1 (pS2), EBAG9, and Cathepsin D (Augereau
et al., 1994; Berry et al., 1989; Ikeda et al., 2000), and
the proximal promoters of target genes that lack EREs,
including c-Myc and IGF-I, contain AP-1 and Sp-1 sites
that appear essential for transcription in in vitro repor-
ter assays (Dubik and Shiu, 1992; Umayahara et al.,
1994). Few, if any regulatory elements at significant dis-
tances from the mRNA start sites of target genes have
been shown to be directly targeted by ER, and compu-
tation approaches to identify novel ER binding domains
have focused primarily on gene proximal regions (Bajic
and Seah, 2003; Bourdeau et al., 2004). However, more
progress has been made in studies of b-globin gene
regulation which has contributed to our understanding
of general mechanisms of transcriptional regulation
and has shown that locus control regions (LCR) up to
25 kb from the gene are capable of enhancing gene
transcription (recently reviewed in Bulger et al. [2002]).
In this study, we have undertaken an unbiased ap-
proach to identify all regulatory regions that may play a
role in ER-mediated transcription by combining chro-
matin immunoprecipitation (ChIP) analyses of in vivo
ER-chromatin complexes with Affymetrix tiled oligonu-
cleotide microarrays that cover the entire nonrepetitive
sequences of chromosomes 21 and 22, including, im-
portantly, all the intergenic regions. Most previous
ChIP-microarray studies have focused primarily on pro-
moter regions (Odom et al., 2004) or CpG islands, which
represent promoter-rich sequences (Weinmann et al.,
2002). The tiled arrays used here are composed of 25
bp probes located at 35 nucleotide resolution (Cawley
et al., 2004; Kapranov et al., 2002) and permit the op-
portunity to interrogate previously unexplored regions
of chromosomal DNA. The 780 characterized or pre-
dicted genes on chromosomes 21 and 22 represent
about 2% of the total number of genes (Kapranov et
al., 2002) and thus provide a representative model for
Cell
34the unbiased identification of ER-mediated gene regu- g
clation paradigms.
Here we find a discrete number of ER binding sites i
1across chromosomes 21 and 22, almost all of which are
in nonpromoter proximal regions. We explored under- r
2lying biological patterns within the list of genuine
chromatin-interacting domains and identified common 5
omotifs highly enriched in these regions. Using this infor-
mation, we prove that the distal ER binding sites are d
sdiscrete chromatin regions involved in transcriptional
regulation and that a Forkhead protein, at these sites, D
bis required for activity by ER.
i
aResults
o
fER Occupies a Limited Number of Binding
tSites on Chromosomes 21 and 22
tEstrogen-dependent MCF-7 breast cancer cells were
sdeprived of hormones and stimulated with estrogen or
tvehicle for 45 min, a time we have previously shown to
ehave maximal recruitment of ER to the promoters of
kseveral known gene targets, including Cathepsin D and
sTFF-1 (Shang et al., 2000). Following ChIP, ER-associ-
dated DNA was amplified using nonbiased conditions,
tlabeled, and hybridized to the tiled microarrays. Rela-
stive confidence prediction scores were generated by
quantile normalization across each probe followed by
San analysis using a two-state Hidden Markov model
C(Rabiner, 1989). These scores included both probe in-
ttensity and width of probe cluster. Triplicate experi-
Ements eliminated stochastic false positives, after which
bpeaks that reproducibly appeared at least twice in the
wthree replicates were included. Real-time PCR primers
uwere designed against numerous peaks in the list, and
Edirected ER ChIP was conducted to identify the bound-
sary between the true ER binding peaks (>1.5-fold en-
frichment over input) and the false positives (data not
cshown) and generate the final list of 57 estrogen-stim-
iulated ER binding sites within 32 discrete clusters (Fig-
nures 1A and 1B and see the Supplemental Raw Data
Ein the Supplemental Data available with this article
online).
As one example of the validity of this method, the A
Alocalization of ER to the proximal promoter 400 bp re-
gion of the estrogen-regulated gene, TFF-1, was ob- E
bserved. A functional ERE had been previously mapped
to the region 393 to 405 bp upstream from the tran- M
iscription start site of TFF-1 (Berry et al., 1989). Further-
more, a region 10.5 kb upstream of the TFF-1 tran- T
tscription initiation site (Figure 1A) was also found to be
bound by ER. Interestingly, an estrogen-inducible DNase a
sI hypersensitive site has been previously mapped 10.5
kb upstream from the TFF-1 start site (Giamarchi et al., w
g1999), though the region had not been further charac-
terized. Our data now define these regions as authentic e
EER binding sites.
Within the small list of 57 ER binding sites, we ob- N
lserved 32 ER binding clusters, some of which were
proximal to genes previously implicated as estrogen tar- D
egets, including the transcription factor XBP-1, DSCAM-1,
and the nuclear receptor coregulator NRIP-1 (Cavailles w
det al., 1995; Pedram et al., 2002; Wang et al., 2004).
Binding sites were also observed within 200 kb from Eenes not previously implicated as estrogen targets, in-
luding SOD-1, a superoxide dismutase gene involved
n scavenging oxygen-free radicals (Beckman et al.,
993; Singh et al., 1998) and implicated in tamoxifen-
esistant progression in MCF-7 xenografts (Schiff et al.,
000). None of these genes recruited ER to a proximal
# promoter region, but possessed divergent patterns
f association. The XBP-1 gene, recruited ER to three
istinct and discrete regions 13.2 kb to 22.9 kb up-
tream of the transcription start site (Figure 1B).
SCAM-1 contained a clustering of ten intronic ER
inding sites, more than 0.5 Mb from the transcription
nitiation site. NRIP-1 contained six ER binding sites in
region of chromosome 21 well known for its scarcity
f genes (Katsanis et al., 1998). 5# RACE was per-
ormed on NRIP-1 to determine the exact location of
he transcription start site and the distance between
he ER binding sites and the genuine transcriptional
tart site. Sequencing of the 5# terminus of the NRIP-1
ranscript after estrogen stimulation revealed the pres-
nce of two previously missed exons for NRIP-1, 74.96
b and 97.39 kb from the previously annotated gene
tart site (data not shown). Therefore, the ER binding
omains exist 107 to 144 kb from the genuine transcrip-
ion start site of NRIP-1. The locations of all binding
ites in relation to genes can be found in Table S1.
The ER binding sites adjacent to TFF-1, XBP-1,
OD-1, NRIP-1, and DSCAM-1 were validated by ER
hIP and standard PCR (Figures 2A–2E). Also, quantita-
ive PCR was performed on each of these sites after
R ChIP (Figure 2F), confirming these putative in vivo
inding sites as genuine ER binding sites. To test
hether these discrete ER recruitment regions were
nique to estrogen action in MCF-7 cells, we performed
R ChIP and directed real-time PCR against the same
ites in T47-D breast cancer cells. These data con-
irmed that the majority of the sites identified in MCF-7
ells were also regions of estrogen-dependent ER bind-
ng in a second ER-positive breast cancer cell line (data
ot shown), highlighting the conservation of specific
R-chromatin association sites.
Significant Number of ER Binding Sites Reside
djacent to Estrogen Gene Targets
strogen-mediated transcript changes were identified
y converting RNA from vehicle or estrogen-stimulated
CF-7 cells into double-stranded cDNA and hybridiz-
ng to the chromosome 21 and 22 tiled microarrays.
hirty-five genes (4.4% of all genes) appeared to be
ranscribed, after which real-time primers were made
gainst all these transcripts and quantitative RT-PCR
howed that 12 transcripts on chromosomes 21 and 22
ere estrogen induced (Table 1). Eleven of these twelve
enes had ER binding clusters within 200 kb. The only
strogen-regulated gene that did not have an adjacent
R binding cluster was ATP5J. TFF-1, XBP-1, and
RIP-1 were in the small list of 1.5% of genes upregu-
ated following estrogen stimulation (Supplemental Raw
ata). DSCAM-1 and SOD-1 were not upregulated by
strogen stimulation at the 3 hr time point assessed but
ere transcribed after 6 hr of estrogen stimulation, as
etermined by RT-PCR (Figure S2). This delay between
R association and transcription of DSCAM-1 and
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35Figure 1. Map of ER Binding Sites on Chromosomes 21 and 22 after Estrogen Stimulation
The visual representation of ER binding sites on chromosomes 21 (A) and 22 (B) are shown. Gene locations are shown in blue bars. Gene
locations are based on the April 2003 genome freeze in the UCSC browser using Genbank RefSeq positions. Predicted EREs are shown as
black bars and ER binding sites are shown as red bars.
(A) An expanded view of the TFF-1 gene region is shown as signal difference between ER ChIP and Input DNA for both the estrogen- and
vehicle-treated cells. The TFF-1 gene is shown in its genuine 3#-5# orientation. The gene adjacent to TFF-1 is not an estrogen target.
(B) Expanded view of the XBP-1 gene region on chromosome 22. The XBP-1 gene is shown in its genuine 3#-5# orientation.SOD-1 may be a consequence of a requirement for
subsequent modification of the receptor complex or the
requirement for the production of other factors involved
in ER action but not necessarily part of an ER complex.
Regardless of the mechanism for the transcriptional
delay, it now appears that early and at least some de-
layed estrogen-regulated genes recruit the receptor
with the same kinetics. This implies that events subse-
quent to ER binding are responsible for timing the initia-
tion of transcription of these delayed targets.Distal ER Binding Domains Function
as Transcriptional Enhancers
The significant sequence distance between many of the
ER binding sites and the putative target gene compli-
cates their functional validation. However, we explored
the possibility that these ER binding sites may recruit
components indicative of transcriptional activation.
RNA PolII ChIP followed by real-time PCR was per-
formed on a subset of the putative regulatory regions
adjacent to TFF-1, XBP-1, DSCAM-1, NRIP-1, and
Cell
36Figure 2. Validation of the In Vivo Binding of
the Transcription Complex to Regulatory Re-
gions
ChIP of ER and standard PCR of sites adja-
cent to TFF-1 (A), XBP-1 (B), DSCAM-1 (C),
NRIP-1 (D), and SOD-1 (E). TFF-1 nonspe-
cific and XBP-1 promoter primers were in-
cluded as negative controls. The lanes are
vehicle (V), estrogen (E), and Input (I).
(F) ChIP of ER, RNA PolII, AIB-1, or IgG con-
trol and real-time PCR of binding regions.
The data are estrogen-mediated fold enrich-
ment compared to vehicle (ethanol) control.
The color intensity reflects the fold change
as described in the legend. TFF-1 nonspe-
cific and XBP-1 nonspecific primers were in-
cluded as negative controls. The data are the
average of three replicates ± SD.SOD-1 genes. Interestingly, RNA PolII association was t
aseen with all of these sites in an estrogen-dependent
manner (Figure 2F). Furthermore, ChIP of AIB-1, an on- e
ecogenic ER coactivator (Kuang et al., 2004; Torres-
Arzayus et al., 2004), confirmed that AIB-1 is also present t
ton all of these “regulatory” sites following estrogen ex-
posure (Figure 2F). As negative controls, primers were t
cdesigned against the intergenic region between the
TFF-1 promoter and enhancer and against a region 7 B
pkb from XBP-1 enhancer 3. Neither ER nor any of the
other factors were found associated with these control r
aregions. In addition, we examined the promoter of
XBP-1. Although ER protein association was not ob- m
aserved at the XBP-1 promoter, RNA PolII was found
enriched at this site supporting the hypothesis that e
EXBP-1 is transcriptionally activated by ER.
To explore the possibility that the distal enhancer re- c
sgions not only function as sites of protein recruitment
but physically play a role during transcription of the ad-
ojacent gene, we performed a chromosome capture as-
say (Dekker et al., 2002) to assess whether promoter t
tand enhancer sequences were components of the
same chromatin regions. Hormone-depleted MCF-7 h
Ecells were stimulated with vehicle or estrogen, and the
fixed chromatin was digested with a specific restriction t
tenzyme (BtgI), followed by ER ChIP and ligation. After
ligation, the ligated chromatin mix was washed and the s
pcrosslinking was reversed. One primer in the TFF-1 pro-moter and one primer in the TFF-1 enhancer were usedo PCR potentially ligated fragments of DNA (Horike et
l., 2005). As seen in Figure 3A, TFF-1 promoter and
nhancer DNA was ligated together only in the pres-
nce of estrogen, confirming that estrogen-mediated
ranscription of TFF-1 involves direct physical interac-
ion between the enhancer and promoter. No interac-
ion was seen in the no-digestion control or no-ligation
ontrol. We performed the same experiment using the
smI restriction enzyme that cuts the genuine NRIP-1
romoter (as determined by 5# RACE) and enhancer 3
egion. Remarkably, after ligation, we were able to PCR
1 kb fragment that corresponded to the ligated pro-
oter-enhancer regions using one promoter-specific
nd one enhancer-specific primer (Figure 3B). This
strogen-dependent interaction of the distal (144 kb)
R binding site with the promoter of the NRIP-1 gene
onfirms the authenticity of these distal sites as tran-
criptional regulatory domains.
The finding that RNA PolII is recruited to the majority
f ER binding sites, even those removed from known
ranscription sites, led us to investigate the possibility
hat these binding sites can function as genuine en-
ancers. To this end, we cloned 23 ER sites (40% of all
R binding sites) into a pGL-3 luciferase vector con-
aining an SV40 promoter and transfected these vec-
ors into hormone-depleted MCF-7 cells which where
ubsequently treated with estrogen or vehicle control.
GL-3 empty vector was used as a negative control,and transfections were normalized with pRL null. Al-
Large-Scale Mapping of Estrogen Receptor Binding
37Table 1. List of ER Binding Site Clusters and Relative Locations to
Putative Gene Targets
Number Closest
Cluster of Binding Regulated
Number Sites Start Stop Gene
1 1 21: 10048850 10049271
2 1 14600251 14600737
3 1 15171656 15172273
4 6 15467150 15738864 NRIP-1
5 1 17422343 17422868
6 1 21532885 21533421
7 1 29151881 29152882
8 1 31821967 31822715 SOD-1
9 2 35021165 35027898
10 1 35510057 35510719
11 2 36480740 36487032
12 1 38635468 38636783
13 10 40363341 40675801 DSCAM-1
14 1 41911683 41912284
15 1 42005946 42006169 PRDM15
16 2 42680784 42691725 TFF-1
17 1 42830736 42831350
18 1 43564518 43565261 NDUFV3
19 2 45606461 45663897
20 1 45790004 45790654 Col18A1
21 2 22: 17159455 17194014
22 1 19566341 19566809
23 3 19822950 19945255
24 3 27534171 27543908 XBP-1
25 1 28106122 28107112 AP1B1
26 1 28237489 28238464
27 1 28519139 28520023
28 2 30300284 30307434 PISD
29 2 37030766 37033295
30 1 39371665 39372232
31 1 41361325 41361720 Predicted
32 1 45100090 45100552
The 32 transcriptional clusters are shown, with the start and stop
locations of the ER binding sites.most 75% of the ER binding domains contained estro-
gen-induced enhancer characteristics in an in vitro
transcription model (Figure 3C), supporting the hypoth-
esis that the distal binding sites play transcriptional
regulatory roles.
ER Binding Sites Are Conserved Across Species
To identify if the ER binding sites are conserved be-
tween human and mouse genomes, we assessed the
identity in sequence in a window of 6 kb from the center
of all 57 ER binding sites. This conservation was
mapped within a 500 bp window at a single nucleotide
resolution and confirms a strong conservation at the
center of the ER binding site and the 500 bp on either
side of the middle of the peak (Figure 4A). However,
conservation decreased to background levels at a dis-
tance of 1 kb or more from the center of the ER binding
sites. This supports the hypothesis that the discrete ER
binding sites we see in MCF-7 cells are conserved be-
tween species and likely play a more general role in ER
action in other cellular systems.
A Screen for Common Sequences Enriched
in Genuine ER Binding Regions Suggests the
Importance of Forkhead Factors in Estrogen Action
An unbiased search for common sequence motifs (Liu
et al., 2002) within the 57 individual ER binding sites onchromosomes 21 and 22 revealed the significant recur-
rence of two motifs. A consensus 15 base sequence
identical to the canonical ERE was present in 49% of
all the ER binding sites on chromosomes 21 and 22
(Figure 4B; Klinge, 2001). The likelihood of an ERE oc-
curring in one of the ER binding sites was significantly
increased when compared to all of chromosomes 21
and 22 (p = 1.33E-15). In the ER binding sites lacking a
canonical ERE, a majority were found to contain one or
more ERE half-sites, and the occurrence of ERE half-
sites was also nonrandom (p = 2.16E-14). To confirm
that our failure to find ER binding at other EREs (5500
predicted EREs on chromosomes 21 and 22, as listed
in Figures 1A and 1B) was not due to the insensitivity
of our ChIP-microarray technique, we performed ChIP
for ER followed by PCR for several randomly selected,
predicted but nonfunctional perfect EREs on chromo-
somes 21 and 22. No ER association was found at any
of these sites (data not shown).
We next determined whether DNA sequences other
than the classical ERE were found at the ER binding
sites by analyzing the bound sequences for conserved
motifs after removing the EREs. This analysis revealed
the presence of a Forkhead factor binding site in 54%
of the 57 ER binding regions (Figure 4B), a finding that
would only occur by chance with a probability of p =
1.23E-8. Forkhead binding motifs were found in 56% of
the ER binding regions that contain a canonical ERE.
Using the consensus Forkhead motif recurring within
these regions (Figure 4B), we determined the prob-
ability of this motif residing within predicted ERE re-
gions that are not bound by ER in vivo (18.45%). This
significant enrichment of a Forkhead motif within ER
binding regions (p = 3.78E-7) suggested the presence
of adjacent Forkhead motifs may play a role in deter-
mining ER binding. The finding that the largest category
of sites contains both an ERE and a Forkhead motif
(47.4%) strongly suggests a functional interaction (Fig-
ure 4C).
Forkhead Proteins Play a Combinatorial
and Essential Role in ER Binding
and ER-Mediated Gene Transcription
A combinatorial interaction between Forkhead and ER
pathways has been previously suggested for a small
number of specific genes. HNF-3α (FoxA1) Forkhead
binding domains within the promoter of the estrogen-
regulated genes TFF-1 (Beck et al., 1999) and Vitello-
genin B1 (Robyr et al., 2000) have been shown to be
important for gene transcription, and they have been
shown to interact directly with ER in yeast two-hybrid
experiments (Schuur et al., 2001). The function of Fork-
head proteins can be regulated by their nuclear-cyto-
plasmic distribution depending on their phosphoryla-
tion (Brunet et al., 1999; Kops et al., 1999). We therefore
determined that FoxA1 localized to the nucleus before
and after estrogen stimulation of MCF-7 cells (data
not shown).
We next determined whether FoxA1 was recruited
along with ER to the ER binding domains. Directed
ChIP of FoxA1 followed by real-time PCR of all 57 ER
binding regions on chromosomes 21 and 22 revealed a
high degree of concordance between regions that re-
cruit ER and FoxA1. Approximately 48% of all of the ER
Cell
38Figure 3. Interaction of Promoter-Enhancer
Domains and Transcriptional Activity of En-
hancer Regions
(A) Chromosome capture assay was per-
formed after digesting fixed chromatin from
vehicle- or estrogen-treated cells with the
BtgI restriction enzyme. Primers flanking the
TFF-1 promoter and enhancer were used to
amplify DNA after ligation. Undigested con-
trols and no ligase controls were included.
(B) Chromatin was digested with BsmI, and
one primer flanking the NRIP-1 promoter and
one in enhancer 3 region were used to am-
plify a specific product after ligation.
(C) ER binding sites were cloned into the
pGL-3 promoter vector and transfected into
hormone-depleted MCF-7 cells, after which
vehicle (open bars) or estrogen (solid bars)
was added. Empty pGL3-promoter vector
was used as a negative control. Cotransfec-
tion of pRL null Renilla vector was included
as a normalizing control. The data are the
average of three replicates ± SD.binding domains showed FoxA1 interaction, although m
tthe pattern of recruitment differed from site to site (Fig-
ure S3). A majority of the regions containing FoxA1 did d
uso in the absence of estrogen, but FoxA1 binding was
decreased following estrogen stimulation. This was the P
wcase for NRIP-1 enhancer 1, DSCAM-1 enhancer 1, and
TFF-1 promoter (Figure 5A). FoxA1 association with p
XXBP-1 enhancer 2 was clearly observed but was not
diminished after estrogen addition (Figure 5A). All of a
cthese ER binding sites contained a Forkhead motif and
an ERE or ERE half-site (Figure 5B). FoxA1 was not f
seen to bind to XBP-1 enhancer 3, which lacks a Fork-
head motif (Figure 5). However, several regions contain- a
wing Forkhead motifs did not recruit FoxA1, and several
ER binding domains that lacked Forkhead motifs did e
tbind FoxA1. This complex interplay between FoxA1,
ER, and binding sites within chromatin likely involves h
gadjacent regions to the ER binding sites and may in-
volve other proteins. Despite this, it is clear that a sig- T
gnificant proportion of ER binding sites, especially those
adjacent to actively transcribed genes, contain FoxA1 (
cprior to estrogen stimulation and ER recruitment to the
same regions. F
tTo determine the importance of FoxA1 in mediating
ER association with chromatin, we developed siRNA to g
the 3#UTR of FoxA1 mRNA. Specific targeted knock-
down of FoxA1 protein was achieved (Figure 6A), with- D
out changes in control protein or ER protein levels (data
not shown). A luciferase siRNA (siLuc) was used as a A
negative control. MCF-7 cells were deprived of hor-ones for 24 hr and siLuc, or siRNA to FoxA1, was
ransfected for 6 hr, after which hormone-depleted me-
ia was added for a further 48 hr and cells were stim-
lated with estrogen or vehicle. ER ChIP and real-time
CR of a number of previously validated binding sites
as performed. The decrease in FoxA1 completely im-
eded the ability of ER to bind to TFF-1 promoter,
BP-1 enhancer 1, and NRIP-1 enhancer 2 (Figure 6B),
s well as DSCAM-1 enhancer 1 (data not shown). No
hanges were observed on the XBP-1 promoter, which
unctioned as a negative control (Figure 6B).
Since the targeted knockdown of FoxA1 inhibited the
bility of ER to associate with in vivo ER binding sites,
e assessed the effect of Forkhead downregulation on
strogen-mediated transcription. After siLuc or siFoxA1
ransfection, cells were stimulated with estrogen or ve-
icle for 6 hr and mRNA changes in all 12 estrogen tar-
et genes on chromosomes 21 and 22 were assessed.
he estrogen-induced increases in all 12 estrogen tar-
ets were abolished when FoxA1 was downregulated
Figure 6C), but no changes were observed in GAPDH
ontrol mRNA levels. The essential role for the FoxA1
orkhead protein during transcription of all estrogen
arget genes on chromosomes 21 and 22 confirms a
eneral requirement of FoxA1 for ER transcription.
iscussion
complete picture of ER-mediated gene activation has
begun to emerge in recent years, with a coordinated
Large-Scale Mapping of Estrogen Receptor Binding
39Figure 4. Conservation of ER Binding Sites
and Presence of Enriched Motifs
(A) Sequence homology of ER binding sites
and surrounding sequence between human
and mouse genomes. The center of ER peaks
is designated coordinate 0.
(B) An unbiased motif screen of all the ER
binding sites on chromosomes 21 and 22
revealed the presence of two enriched mo-
tifs, an ERE and a Forkhead binding motif,
both of which are visually represented in
WebLogo (http://weblogo.berkeley.edu).
(C) The occurrence of ERE or ERE half-sites
and Forkhead sites within the 57 ER binding
sites on chromosomes 21 and 22.and timely cycling of receptor, nuclear coactivators,
chromatin remodelling proteins, and the transcription
machinery on and off target promoters (Metivier et al.,
2003; Shang et al., 2000). However, these studies over-
simplify the problem by focusing on the promoter proxi-
mal region of one or two target genes and largely ignore
the remaining chromosomal sequence. Here, we have
interrogated the association of ER across entire chro-
mosomes, including intergenic regions that contain po-
tential cis-regulatory domains. These ChIP-microarray
experiments demonstrate the ability to identify genuine
in vivo ER protein binding sites in previously unex-
plored regions of the genome. Interestingly, while a few
of the ER binding sites were found directly adjacent to
ER target genes, most were found at significant dis-
tances including several >100 kb removed from tran-
scription start sites. Of the 57 ER binding sites (within
32 potential transcriptional regulatory clusters), only a
very small number of proximal promoters recruited ER,
despite the fact that the other genes were estrogen in-
duced. The presence of multiple components of the
transcriptional machinery at distal sites combined withthe ability of chromosome conformation capture assays
to demonstrate that these distant sites are physically
associated with promoter-proximal regions suggests
that they play an important role in estrogen-mediated
regulation.
A significant volume of work has focused on identi-
fying essential domains within the proximal promoters
of known estrogen regulated genes (Dubik and Shiu,
1992; Petz et al., 2002; Porter et al., 1996; Teng et al.,
1992; Umayahara et al., 1994; Vyhlidal et al., 2000;
Weisz and Rosales, 1990). The conclusions drawn from
this large volume of data implicate a number of motifs,
including Sp1, AP-1, and GC-rich regions as important
cis-regulatory domains in ER-mediated transcription.
However, our data demonstrate ER regulatory sites at
distances several orders of magnitude greater than was
focused on in the past, suggesting that they may func-
tion in ways analogous to the b-globin LCR (Sawado et
al., 2003).
Nonbiased motif scanning of the genuine in vivo ER
binding sites identified a canonical ERE in the majority
of ER binding sites that represented only 1.5% of EREs
Cell
40Figure 5. Recruitment of Forkhead Protein to ER Binding Domains
(A) ChIP of FoxA1 followed by real-time PCR of NRIP-1 enhancer
1, DSCAM-1 enhancer 1, TFF-1 promoter, and XBP-1 enhancer 2.
XBP-1 enhancer 3 is included as a control which does not recruit
FoxA1. Data are shown as fold change versus input and are the
average of three replicates ± SD. Open bars are vehicle treated and
solid bars are estrogen treated.
(B) Schematic diagram showing the relative location of ERE motifs
F
o
(inverted green arrows), ERE half-sites (blue arrows), and Forkhead
(motifs (red arrows). Chromosome nucleotide locations are given.
c
vigure 6. Specific Targeted Knockdown of FoxA1 and the Effects
n Estrogen-Mediated Transcription
A) siRNA to FoxA1 was transfected into hormone-depleted MCF-7
ells, and changes in FoxA1 protein levels were determined after
ehicle or estrogen treatment. SiLuc was used as a transfection
control and Calnexin was used as a loading control.
(B) ER ChIP was performed after vehicle or estrogen treatment of
siLuc or siFoxA1 transfected cells and real-time PCR was con-
ducted on TFF-1 promoter, XBP-1 enhancer 1, NRIP-1 enhancer 2,
as well as XBP-1 promoter as a negative control. The data are fold
enrichment over vehicle-treated.
(C) Changes in mRNA levels of all estrogen-regulated genes on
chromosomes 21 and 22 after siLuc or siFoxA1. The data are estro-
gen-mediated fold enrichment compared to vehicle (ethanol) con-
trol and are the average of three separate replicates ± SD. The
color intensity reflects the fold change as described in the legend.predicted by bioinformatics alone. Previous approaches
for motif identification involved computational-based
methods for identifying response elements, after which
gene proximal sites are included as potential binding
domains (Bajic and Seah, 2003; Bourdeau et al., 2004).
The current data suggest that while ER binding involves
interaction with consensus ERE motifs, the presence of
such motifs is insufficient to dictate receptor-chromatin
association. Furthermore, the exclusion of response el-
ements further than several kilobases from transcrip-
tion start sites eliminates distal regulatory regions that
may be the primary receptor-chromatin interaction l
bsites.
Since the presence of an ERE alone is insufficient to b
rdefine an authentic ER regulatory site, we searched for
other conserved sequences and found that Forkhead t
cfactor binding sites are present near authentic EREs
significantly more frequently than those that do not t
ibind ER. We showed that a Forkhead factor (FoxA1)
binding was essential for ER-chromatin interactions c
tand subsequent expression of estrogen gene targets. A
link between ER and FoxA1 has previously been shown, t
rwith their expression correlated in breast cancer cellines (Lacroix and Leclercq, 2004). FoxA1 protein can
ind condensed chromatin via its winged-helix DNA
inding domains that mimic histone linker proteins (Ci-
illo et al., 2002; Cirillo et al., 1998). Unlike histone pro-
eins however, FoxA1 does not contain the amino acid
omposition to condense chromatin and it therefore is
hought to promote euchromatic conditions. As such, it
s possible that the presence of FoxA1 identifies spe-
ific regions within chromatin to facilitate the associa-
ion of the ER transcription complex. Our data suggest
hat FoxA1 is present on the chromatin at a number of
egions, after which ER can associate with these spe-
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41cific sites. Downregulation of FoxA1 inhibits the ability
of ER to associate with its binding sites, confirming the
requirement for Forkhead-directed association of ER
with chromatin, despite the fact that these sites contain
sufficient information, in the form of an ERE, for ER
docking. This, combined with a recent investigation
showing that FoxA1 can directly modulate chromatin in
the MMTV promoter and can positively enhance tran-
scription by the glucocorticoid receptor (Holmqvist et
al., 2005), supports a general model for FoxA1 involve-
ment in nuclear receptor transcription.
We have taken an unbiased approach to identify re-
gions of chromatin, both promoter proximal and in-
tergenic sequences, which are involved in ER-mediated
transcriptional activity. We find a limited number of
bona fide ER binding sites on chromosomes 21 and 22,
with a significant enrichment of canonical ERE palin-
dromes and half-sites within the binding sites. More-
over, the presence of Forkhead binding motifs and the
subsequent identification of a functional role for the
Forkhead protein FoxA1 in estrogen signaling exempli-
fies the power of this approach to identify important
regulatory domains within the vast regions of unex-
plored sequence of the human genome.
Experimental Procedures
Chromatin Immunoprecipitation (ChIP)-Microarray Preparation
ChIP was performed as previously described (Shang et al., 2000),
with the following modifications. Two micrograms of antibody was
prebound for a minimum of 4 hr to protein A and protein G Dynal
magnetic beads (Dynal Biotech, Norway) and washed three times
with ice-cold PBS plus 5% BSA and then added to the diluted chro-
matin and immunoprecipitated overnight. The magnetic bead-chro-
matin complexes were collected and washed six times in RIPA
buffer (50 mM HEPES [pH 7.6], 1 mM EDTA, 0.7% Na deoxycholate,
1% NP-40, 0.5 M LiCl). Elution of the DNA from the beads was as
previously described (Shang et al., 2000). Antibodies used were as
follows: ERα (Ab-10) from Neomarkers (Lab Vision, United King-
dom), ERα (HC-20), RNA PolII (H-224), AIB-1/RAC3 (C-20), HNF-3α/
FoxA1 (H-120), mouse IgG (sc-2025), and rabbit IgG (sc-2027) from
Santa Cruz (Santa Cruz Biotechnologies, California). Ligation-Medi-
ated PCR was performed as previously described (Ren et al., 2002).
Labeling was performed as previously described (Kapranov et al.,
2002). Microarrays used were Affymetrix Genechip chromosome
21/22 tiling set P/N 900545.
Data Analysis
1,054,325 probe pairs were mapped to chromosomes 21 and 22
according to the NCBIv33 GTRANS Libraries provided by Affymet-
rix. (PM-MM) value was recorded for each probe pair, and a probe
pair was removed if either PM or MM was flagged as outlier by the
Affymetrix GCOS software. The samples (three ER+ ChIP and three
genomic inputs) were normalized by quantile normalization (Bol-
stad et al., 2003) based on a combined 76 ChIP experiments ob-
tained from public domain and Dana-Farber Cancer Institute. The
behavior of every probe pair i, assumed to be N(mi, si2), was esti-
mated from the 76 normalized experiments. A two-state (ChIP-
enriched state and nonenriched state) Hidden Markov Model with
the following parameters was applied to each sample to estimate
the probability of ChIP enrichment at each probe pair location:
Transition probabilities: 300/1,054,325 for transition to a dif-
ferent state,
1 − (300/1,054,325) for staying in the same state.
Emission probabilities: N(mi, si2) for nonenriched hidden state,
N(mi + 2si,(1.5si)2) for enriched hidden state.
To combine the results from the six samples, an enrichmentscore was calculated as the average enrichment probability in the
three ER+ ChIP samples subtracted by the average enrichment
probability in the three genomic input samples. Since the tiling ar-
ray has one 25-mer probe in every 35 bp of nonrepeat regions, the
coverage of every probe was extended by 10 bp on both ends. An
enriched regions is defined as run of probes with enrichment score
>50% and covering at least 125 bp. Each enriched region can toler-
ate up to two neighboring probes with enrichment score between
[10%, 50%]. If two neighboring probes are more than 210 bp apart,
the enriched region is broken into two separate blocks. A summary
enrichment score was obtain for each enriched region, which is the
enrichment score summation for all the probes in the region divided
by the square root of the number of probes in the region. This
summary enrichment score represents the relative confidence of a
predicted enriched region.
Sequence Analysis
The genomic DNA of every ChIP-enriched region was retrieved
from UCSC genome browser and ranked by the summary enrich-
ment score. MDscan algorithm (Liu et al., 2002) was applied to the
sequences to find enriched sequence pattern that is the putative
estrogen receptor binding motif. To find a motif of width w, MDscan
first enumerates each w-mer in the highest ranking sequences and
collects other w-mers similar to it in these sequences to construct
a candidate motif as a probability matrix. A semi-Bayes scoring
function was used to remove low-scoring candidate motifs and re-
fine the rest by checking all w-mers in all the ChIP-enriched se-
quences. A high-scoring motif (with similar consensus) consistently
reported multiple times at different motif widths indicates a strong
prediction.
We expanded all 57 of the ER binding sites equally in each direc-
tion to have a length of 6 kb. The human-mouse conservation score
of each nucleotide in the expanded binding region is defined as
the average sequence identity (# matched nucleotides − # indels)/
500 of a 500-mer window centered at the nucleotide. The human
(hg15) /mouse (mm3) BLASTZ (Schwartz et al., 2003) genome align-
ments were downloaded from http://genome.ucsc.edu.
Real-Time PCR
Primers were selected using Primer Express (Applied Biosystems).
Five microliters of precipitated and purified DNA was subjected to
PCR using the Applied Biosystems SYBR Green Mastermix. Rela-
tive DNA quantities were measured using the PicoGreen system
(Molecular Probes, Oregon). All primer sequences and locations
are listed in Table S2.
Double-Stranded cDNA Synthesis
Total RNA was converted to double stranded cDNA according to
the Invitrogen Superscript double-stranded cDNA synthesis manu-
facturer’s instructions. The RNA was primed with 250 ng oligo(dT)
(Invitrogen) and 25 ng random hexamers (Gibco). cDNA was frag-
mented and labeled as described above.
5RACE
5# RACE was performed according to the manufacturer’s instruc-
tions (Invitrogen). The primers sequences used were as follows:
NRIP-1 RT primer (5#-TGCCTGATGCATTAGTAATCC-3#), NRIP-1
nested primer 1 (5#-GAGCCAAGCTCTTCTCCATGAGTCATGTTC-3#),
and NRIP-1 nested primer 2 (5#-ACCTTCCATCGCAATCAGAGA
GAGACGTACTG-3#). The PCR product was cloned and sequenced
by standard methods.
Chromosome Capture Assay
Fixed chromatin was digested overnight with specific restriction
enzymes after which ER ChIP was set up as described above. After
overnight ChIP, the beads were precipitated and resuspended in
ligation buffer (NEB, Massachusetts) and overnight ligation was
performed. The beads were collected, washed, and the formalde-
hyde crosslinking was reversed as described above. Primers used
to amplify annealed fragments were as described in Table S2.
Cell
42Luciferase Enhancer Activity t
1ER binding sites were amplified by PCR and cloned into the pGL-
3-promoter vector (Promega). Hormone-depleted MCF-7 cells were B
transfected with each of the ER binding domain vectors with Lipo- B
fectamine 2000 (Invitrogen), and total protein lysate was harvested G
after estrogen or ethanol addition for 24 hr. Transfections were nor- m
malized by the cotransfection of the pRL null renilla luciferase vec-
Btor and renilla and firefly luciferase activity was assessed using the
Adual luciferase kit (Promega).
A
F
Western Blotting
BSDS-PAGE was performed as previously described (Carroll et al.,
C2000). Antibodies used were FoxA1/HNF-3α (ab5089), from AbCam
a(Cambridge, United Kingdom) and Calnexin (H-70) from Santa
Cruz (California). C
(
MShort Interfering (si) RNA
EA 21 bp siRNA was designed against the FoxA1 transcript and syn-
3thesized by Dharmacon (Lafayette, Colorado). siRNA was trans-
fected using Lipofectamine 2000 (Invitrogen). The siRNA se- C
quences used were as follows: siFoxA1 sense 5#-GAGAGAAAAAA n
UCAACAGC-3# and antisense 5#-GCUGUUGAUUUUUUCUCUC-3#; t
siLuc sense 5#-CACUUACGCUGAGUACUUCGA-3# and antisense 3
5#-UCGAAGUACUCAGCGUAAGUG-3#. C
K
A
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Supplemental Data include four figures, two tables, and raw data r
files and can be found with this article online at http://www.cell.
Ccom/cgi/content/full/122/1/33/DC1/.
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